Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.7 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 14.9× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| RGEN | VWO | |
|---|---|---|
Market Cap | $11.31B | $168.50B |
Volume | 1,216,919 | 5,654,578 |
Sector | Health | — |
52-Week High | $194.57 | $61.44 |
52-Week Low | $102.87 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VWO trades at $59.68, down 0.08% on the day, with a neutral technical signal. The ETF's performance is influenced by mixed regional exposures, with strength in Taiwan's AI and semiconductor sectors but headwinds from China's economic slowdown. Recent news highlights institutional accumulation and comparisons with other international ETFs, emphasizing its emerging markets focus and 0.06% expense ratio.
The outlook for VWO hinges on emerging market dynamics, particularly tech growth in Taiwan versus China's recovery. Risks include concentrated regional exposure and currency fluctuations. Analyst sentiment is balanced, with technical indicators neutral but institutional interest growing, suggesting cautious optimism for long-term diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
